|4,170 professionals from the world of tourism, technology and investment in Europe and the Americas have shared their vision and defend the “immunity passport”
5.76% of the respondents declare that they have passed the COVID19 and are immunized. Of the respondents, 59.71% are from EMEA, 34.53% from LATAM and 5.7% from the US-Canada.
48.92% of respondents defend the need to create an “immunity passport”. 50.36% indicates that people with verified immunity should be able to avoid sanitary controls on access to flights, hotels and other tourist services, in addition to proving their immunity.
56% consider it irrelevant to have a face-to-face meeting that the person with whom they meet is immunized; and more than 80% do not consider immunity as an element to consider when choosing the member of the sales force to travel.
As for whether the company’s Travel Policy should address immunity, 47.48% say yes; on the other hand, regarding the Meetings and Events Policy, 53.24% say no. 62.59% declare that the immunized population should not be considered as a different segment in a tourism marketing campaign.
Dr. Javier González-Soria, founder of Travelthink, in the Whitepaper that he has prepared from the survey, points out: “The concept of the“ immunity passport ”is linked to the preferential access of travellers to means of transport and accommodation and leads us to the idea that security protocols must be especially effective before the traveller begins their journey, at the origin, and not wait for their application when they have reached their destination. Therefore, the aforementioned concept must be understood broadly, not strictly as a passport, and must evolve in its interpretation as circumstances evolve. ”
In the aforementioned Whitepaper, it is explained that the “immunity passport” must include both tests, in the event that there are no vaccines, as well as vaccines. In the case of COVID19, until we have a vaccine, it is essential that control is required at the origin of travellers, that is, in their own countries. Airlines should require a valid PCR, Serology or alternative test, performed prior to the date of travel, as an essential requirement to obtain the boarding pass. This logic removes the problem of testing outside airports so that it is managed by the public and private health systems of each of the countries of origin of the travellers.